Document:

exv10w3

Exhibit 10.3

December __, 2008

Via Hand Delivery

[Name]

Alexza Pharmaceuticals, Inc.

2091 Stierlin Court

Mountain View, CA 94043

			
	Re:	 	Change of Control Agreement

Dear [Name]:

In consideration of your continued employment, Alexza Pharmaceuticals, Inc. (the “Company”) is
pleased to offer you the following agreement regarding your severance benefits (the “Agreement”).
This Agreement amends and supersedes any and all prior agreements with respect to your severance
benefits and any such prior agreements are hereby expressly superseded and replaced in their
entirety by this Agreement and shall have no further force or effect.

     1. At-Will Employment. Nothing in this Agreement alters the at-will nature of your employment
relationship with the Company. Subject to the terms of this Agreement, either you or the Company
may terminate your employment relationship at any time, with or without Cause or advance notice.
In particular, nothing expressed or implied in this Agreement will create any right or duty on the
part of the Company to have you remain in the employment of the Company or any subsidiary prior to
or following any Corporate Transaction.

     2. Termination. You and the Company each acknowledge that either party has the right to
terminate your employment with the Company at any time for any reason whatsoever, with or without
cause or advance notice pursuant to the following:

          (a) Termination by Death or Disability. In the event you shall die during the period of your
employment hereunder or become permanently disabled, as evidenced by your inability to carry out
your job responsibilities for a continuous period of six months, your employment and the Company’s
obligation to make payments hereunder shall terminate on the date of your death, or the date upon
which, in the sole reasonable determination of the Board of Directors of the Company, you have
failed to carry out your job responsibilities for six months, except the Company shall pay you (or
your estate) (i) any salary earned but unpaid prior to such termination and all accrued but unused
vacation, and (ii) any business expenses incurred by you in connection with your performance of
your duties, according to the policies of the Company, that were incurred but not reimbursed as of
the date of such termination. Vesting of any of your stock options outstanding on the date of
termination shall cease on the date of termination. The Company’s ability to terminate you as a
result of any disability shall be to the extent permitted by state and/or federal law.

1.

 

          (b) Voluntary Resignation. In the event you voluntarily resign from your employment with the
Company (other than for Good Reason as defined below), the Company’s obligation to make payments
hereunder shall cease upon such resignation, except the Company shall pay you (i) any salary earned
but unpaid prior to the resignation and all accrued but unused vacation, and (ii) any business
expenses incurred by you in connection with your performance of your duties, according to the
policies of the Company, that were incurred but not reimbursed as of the date of resignation.
Vesting of any of your stock options outstanding on the date of resignation shall cease on the date
of resignation.

          (c) Termination for Cause. In the event you are terminated by the Company for Cause (as
defined below), the Company’s obligation to make payments hereunder shall cease upon the date of
receipt by you of written notice and explanation of such termination (the “Date of Termination” for
purposes of this paragraph 2(c)), except the Company shall: pay you (i) any salary earned but
unpaid prior to the Date of Termination, all accrued but unused vacation and (ii) any business
expenses, incurred by you in connection with your performance of your duties, according to the
policies of the Company, that were incurred but not reimbursed as of the Date of Termination.
Vesting of any stock options outstanding on the Date of Termination shall cease on the Date of
Termination.

          (d) Termination by the Company Without Cause or Resignation for Good Reason in Connection with
a Corporate Transaction. Subject to the terms and conditions of this Agreement, the Company will
provide you with Severance Benefits (as defined in Section 3) if a Corporate Transaction occurs and
as of, or within three (3) months prior to or twelve (12) months after, the effective time of such
Corporate Transaction (i) the Company terminates your employment without Cause or (ii) you resign
your employment for Good Reason. You will not be entitled to receive any Severance Benefits if (i)
the Company terminates your employment for Cause, (ii) you resign from your employment with the
Company other than for Good Reason, (iii) your employment with the Company terminates as a result
of your death or disability or (iv) the Company terminates your employment without Cause or you
resign your employment for Good Reason other than in connection with a Corporate Transaction as
described in the preceding sentence. In addition, to the extent that any federal, state or local
laws, including, without limitation, so-called “plant closing” laws, require the Company to give
advance notice or make a payment of any kind to you because of your involuntary termination due to
a layoff, reduction in force, plant or facility closing, sale of business, change of control, or
any other similar event or reason, the Severance Benefits payable under this Agreement shall be
reduced in an amount equal to any such payment received by you, such that the total amounts paid
you do not exceed the Severance Benefits specified herein. The Severance Benefits provided under
this Agreement are intended to satisfy any and all statutory obligations that may arise out of your
involuntary termination of employment for the foregoing reasons.

     3. Description of Severance Benefits. For purposes of this Agreement, “Severance Benefits”
are defined as:

          (a) severance pay (the “Severance Pay”) equivalent to twelve (12) months of your Base Salary
(as defined below) plus an amount equal to the greater of (i) the annual bonus paid to you for the
last completed fiscal year and (ii) the amount of your target bonus established for the fiscal year
in which the Notice Date falls; provided that if no target bonus has been

2.

 

established for the fiscal year in which the Notice Date falls, item (ii) shall be the amount
of your target bonus established for the immediately preceding fiscal year. The date you are
notified that your employment with the Company is being terminated without Cause or the date you
notify the Company that you are terminating your employment for Good Reason, shall be referred to
herein as the “Notice Date.” Subject to the final sentence of this Section 3, the Severance Pay
will be paid in a single lump sum cash payment within seven days after the effective date of the
release described below, and will be subject to standard payroll deductions and withholdings;

          (b) all stock options in the Company theretofore granted to you, and any restricted stock
owned by you subject to a right of repurchase by the Company, shall vest immediately upon the
Notice Date; provided that, the relevant stock option plan and such stock options shall not have
otherwise terminated in accordance with the terms thereof; and

          (c) reimbursement of your out of pocket costs to continue your group health insurance benefits
(and dependent coverage, if applicable) under COBRA at substantially the same level of coverage in
effect immediately prior to the Notice Date for eighteen (18) months following the last day of the
month in which your Notice Date occurs, payable in a single lump sum within seven days after the
effective date of the release described below, subject to standard payroll deductions and
withholdings; provided, that even if you do not elect or are not eligible to receive COBRA, you
shall receive the equivalent of such out of pocket costs.

To receive any of the Severance Benefits, you must first sign, date and allow to become effective a
general release of claims in favor of the Company in the form attached hereto as Exhibit A
(the “Release”). Such Release shall not be signed or dated prior to the Notice Date.

To the extent Severance Benefits pursuant to Section 3 above (A) are paid from the date of
termination of your employment through March 15 of the calendar year following such termination,
such Severance Benefits are intended to constitute separate payments for purposes of Section
1.409A-2(b)(2) of the Treasury Regulations and thus payable pursuant to the “short-term deferral”
rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations; (B) are paid following said
March 15, such Severance Benefits are intended to constitute separate payments for purposes of
Section 1.409A-2(b)(2) of the Treasury Regulations made upon an involuntary separation from service
and payable pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations, to the maximum
extent permitted by said provision, and (C) are in excess of the amounts specified in clauses (A)
and (B) of this paragraph, shall (unless otherwise exempt under Treasury Regulations) be considered
separate payments subject to the distribution requirements of Section 409A(a)(2)(A) of the Internal
Revenue Code of 1986, as amended (the “Code”), including, without limitation, the requirement of
Section 409A(a)(2)(B)(i) of the Code that payments be delayed until 6 months after your separation
from service if you are a “specified employee” within the meaning of the aforesaid section of the
Code at the time of such separation from service.

     4. Parachute Payments.

          (a) If any Severance Benefits, payment, distribution or benefit you would receive pursuant to
a Corporate Transaction from the Company or otherwise, but determined without regard to any
additional payment required under this section 4(a), (“Payment”) would

3.

 

(i) constitute a “parachute payment” within the meaning of Section 280G of the Internal
Revenue Code of 1986, as amended (the “Code”), and (ii) be subject to the excise tax imposed by
Section 4999 of the Code or any interest or penalties payable with respect to such excise tax (such
excise tax, together with any such interest and penalties, are hereinafter collectively referred to
as the “Excise Tax”), then you shall be entitled to receive from the Company an additional payment
(the “Gross-Up Payment”) in an amount that shall fund the payment by you of any Excise Tax on the
Payment as well as all income and employment taxes imposed on the Gross-Up Payment, any Excise Tax
imposed on the Gross-Up Payment and any interest or penalties imposed with respect to income and
employment taxes imposed on the Gross-Up Payment.

          (b) The accounting firm engaged by the Company for general audit purposes as of the day prior
to the effective date of the Corporate Transaction shall perform the foregoing calculations. If
the accounting firm so engaged by the Company is serving as accountant or auditor for the
individual, entity or group effecting the Corporate Transaction, the Company shall appoint a
nationally recognized accounting firm to make the determinations required hereunder. The Company
shall bear all expenses with respect to the determinations by such accounting firm required to be
made hereunder.

          (c) The accounting firm engaged to make the determinations hereunder shall provide its
calculations, together with detailed supporting documentation, to the Company and you within
fifteen calendar days after the date on which your right to a Payment is triggered (if requested at
that time by the Company or you) or such other time as requested by the Company or you. If the
accounting firm determines that no Excise Tax is payable with respect to a Payment, it shall
furnish the Company and you with an opinion reasonably acceptable to you that no Excise Tax will be
imposed with respect to such Payment. Any good faith determinations of the accounting firm made
hereunder shall be final, binding and conclusive upon the Company and you.

     5. Description of Corporate Transaction. For purposes of this Agreement, “Corporate
Transaction” is defined as: (i) a sale of substantially all of the assets of the Company; (ii) a
merger or consolidation in which the Company is not the surviving corporation if, immediately after
the merger or consolidation, the stockholders of the Company immediately prior thereto do not
beneficially own, directly or indirectly, either (A) outstanding voting securities representing
more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in
such merger or consolidation, or (B) more than fifty percent (50%) of the combined outstanding
voting power of the parent of the surviving entity in such merger or consolidation, in each case in
substantially the same proportions as their ownership of the outstanding voting securities of the
Company immediately prior to such transaction;; (iii) a reverse merger in which the Company is the
surviving corporation but the shares of the Company’s common stock outstanding immediately
preceding the merger are converted by virtue of the merger into other property, whether in the form
of securities, cash or otherwise if, immediately after the merger, the stockholders of the Company
immediately prior thereto do not beneficially own, directly or indirectly, either (A) outstanding
voting securities representing more than fifty percent (50%) of the combined outstanding voting
power of the surviving entity in such merger or (B) more than fifty percent (50%) of the combined
outstanding voting power of the parent of the surviving entity in such merger, in each case in
substantially the same proportions as their ownership of the outstanding voting securities of the
Company immediately

4.

 

prior to such transaction;; or (iv) any transaction or series of related transactions in which
in excess of 50% of the Company’s voting power is transferred, other than the sale by the Company
of stock in transactions the primary purpose of which is to raise capital for the Company’s
operations and activities.

     6. Definition of Base Salary. For purposes of this Agreement, “Base Salary” means your base
salary as of the Notice Date, excluding the following: any type of bonus payments, commissions,
incentive payments or any other similar remuneration paid directly to you, or any other income
received in connection with stock options, contributions made by the Company under any employee
benefit plan, or similar items of compensation.

     7. Definition of Cause. For purposes of this Agreement, “Cause” means (i) your arrest for
violation of a state or federal criminal law involving the commission of any felony against the
Company; (ii) your intentional, material violation of any material written contract or agreement
between you and the Company (which, if curable, is not cured within twenty (20) days after written
notice thereof by the Company to you); (iv) your unauthorized use or disclosure of the Company’s
confidential information or trade secrets; or (v) your continued gross misconduct (which, if
curable, is not cured within twenty (20) days after written notice thereof by the Company to you).
In the event you are terminated for Cause you will not be entitled to the Severance Benefits, pay
in lieu of notice, vesting of any shares under any option plan, vesting of any unrestricted shares,
or any other such compensation set forth herein, but you will be entitled to all compensation,
benefits and unreimbursed expenses accrued through the date of termination. You and the Company
acknowledge that this definition of “Cause” is not intended and does not apply to any aspect of the
relationship between the Company and any of its employees, including you, beyond determining your
eligibility for the Severance Benefits.

     8. Definition of Good Reason. For purposes of this Agreement, “Good Reason” shall mean one or
more of the following are undertaken by the Company or the surviving entity in the applicable
Corporate Transaction without your express written consent: (i) relocation of your place of work
greater than twenty-five miles from your current work location; (ii) a decrease in your base
salary; (iii) a reduction in the amount of your annual target bonus opportunity as in effect prior
to such decrease; or (iv) a significant diminution in your authority, duties or job
responsibilities as in effect immediately prior to the first announcement relating to the Corporate
Transaction. You and the Company acknowledge that this definition of Good Reason is not intended
and does not apply to any aspect of the relationship between the Company and any of its employees,
including you, beyond determining your eligibility for the Severance Benefits.

     9. Miscellaneous. This Agreement constitutes the complete, final and exclusive embodiment of
the entire agreement between you and the Company with regard to your Severance Benefits. It is
entered into without reliance on any promise or representation, written or oral, other than those
expressly contained herein, and it supersedes any prior or contemporaneous understandings,
discussions, correspondence, agreements, promises, warranties or representations relating to
Severance Benefits. This Agreement may not be modified or amended except in writing signed by you
and a duly authorized officer of the Company. This Agreement will be deemed to have been entered
into and will be construed and enforced in accordance with the laws of the State of California as
applied to contracts made and

5.

 

to be performed entirely within California. The parties agree that any action brought by
either party to interpret or enforce any provision of this Agreement shall be brought in, and each
party agrees to, and does hereby, submit to the jurisdiction and venue of, the appropriate state or
federal court for the district encompassing the Company’s principal place of business.

     10. Successors and Binding Agreement. This Agreement will be binding upon and inure to the
benefit of the Company and any successor to the Company, including without limitation any persons
acquiring directly or indirectly all or substantially all of the business or assets of the Company
whether or not through a Corporate Transaction (and such successor shall thereafter be deemed the
“Company” for the purposes of this Agreement). This Agreement will inure to the benefit of and be
enforceable by your personal or legal representatives, executors, administrators, successors,
heirs, distributees and legatees.

     11. Amendments. No provision of the Agreement may be amended, modified or waived unless such
amendment, modification or waiver shall be agreed to in writing and signed by the Executive and a
duly authorized officer of the Company.

     12. Severability. If any provision of the Agreement shall be determined to be invalid or
unenforceable by a court of competent jurisdiction, the remaining provisions of the Agreement shall
be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by
law.

     13. Independent Counsel. You acknowledge that this Agreement has been prepared on behalf of
the Company by counsel to the Company and that this counsel does not represent, and is not acting
on your behalf. You have been provided with an opportunity to consult with your own counsel with
respect to this Agreement. You understand that the Company does not make any representation or
warranty as to the tax treatment of your stock options.

     14. Counterparts. This Agreement may be executed in one or more counterparts, each of which
shall be deemed to be an original but all of which together will constitute one and the same
agreement.

[remainder of page intentionally left blank]

6.

 

The Company appreciates your continuing contributions to Alexza Pharmaceuticals, Inc. Please sign
below to indicate your understanding and acceptance of this Agreement and return the signed
original to me at your earliest convenience.

Very truly yours,

Alexza Pharmaceuticals, Inc.

	 	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Name:

	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Title:

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Understood and Agreed:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	   
	[Name]

	 	 	 	 	 	Date	 	 

7.

 

Exhibit A

RELEASE

     In exchange for the Severance Benefits provided under the foregoing Change of Control
Agreement with Alexza Pharmaceuticals, Inc. (the “Company”), dated                     , 20___, and except
as set forth in this release:

     I agree to the terms in the foregoing Agreement.

     In consideration of the payment to me of the Severance Benefits set forth in the Agreement, I
hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their
respective officers, directors, agents, servants, employees, attorneys, shareholders, successors,
assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action,
costs, expenses, attorneys fees, damages, indemnities and obligations of every kind and nature, in
law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed,
arising out of or in any way related to agreements, events, acts or conduct at any time prior to
and including the execution date of this release, including but not limited to: all such claims
and demands directly or indirectly arising out of or in any way connected with my employment with
the Company or the termination of that employment; claims or demands related to salary, bonuses,
commissions, stock, stock options, or any other ownership interests in the Company, vacation pay,
fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims
pursuant to any federal, state or local law, statute, or cause of action including, but not limited
to, the federal Civil Rights Act of 1964, as amended; the federal Americans with Disabilities Act
of 1990; the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”); the
California Fair Employment and Housing Act, as amended; tort law; contract law; wrongful discharge;
discrimination; harassment; fraud; defamation; emotional distress; and breach of the implied
covenant of good faith and fair dealing.

     I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have
under the ADEA, as amended. I also acknowledge that the consideration given for the waiver and
release in the preceding paragraph hereof is in addition to anything of value to which I was
already entitled. I further acknowledge that I have been advised by this writing, as required by
the ADEA, that: (a) my waiver and release do not apply to any rights or claims that may arise
after the execution date of this release; (b) I have been advised hereby that I have the right to
consult with an attorney prior to executing this release; (c) I have twenty-one (21) days to
consider this release (although I may choose to voluntarily execute this release earlier); (d) I
have seven (7) days following my execution of this release to revoke the release; and (e) this
release will not be effective until the date upon which the revocation period has expired, which
will be the eighth day after I execute this release.

     I UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS. In
giving this release, which includes claims which may be unknown to me at present, I acknowledge
that I have read and understand Section 1542 of the California Civil Code which reads as follows:
“A general release does not extend to claims

 

 

which the creditor does not know or suspect to exist in his favor at the time of executing the
release, which if known by him must have materially affected his settlement with the debtor.” I
hereby expressly waive and relinquish all rights and benefits under that section and any law of any
jurisdiction of similar effect with respect to my release of any unknown or unsuspected claims I
may have against the Company.

	 	 	 	 	 
	 	 	 
	 

	 	[Name]	 	 
	 
	 	 	 	 
	 

	 	Date:

	 
	 	 	 	 
	 	 	Alexza Pharmaceuticals, Inc.
	 
	 	 	 	 
	 

	 	By:

	 
	 

	 	Name:

	 
	 

	 	Title:exv10w42

Exhibit 10.42

	 	 	 
	 

	 	Alexza Pharmaceuticals, Inc.
	 

	 	ID: 77-0567768
	Notice of Grant of Award

	 	2091 Stierlin Court
	and Award Agreement

	 	Mountain View, CA 94043

	 	 	 	 	 	 	 
	Name:

	 	Award Number:	 	 	 	 
	 

	 	 	 	 	 	 
	Address:

	 	Plan:
	 	 	2005	 

Effective                     , you have been granted an award of                      restricted stock units.
These units are restricted until the vest date(s) show below, at which time you will receive shares
of Alexza Pharmaceuticals, Inc. (the Company) common stock.

The current total value of the award is $                    .

The award will vest in increments on the date(s) shown.

	 	 	 
	Shares

	 	Full
Vest

	 
	By your signature and the Company’s signature below, you and the Company agree
that this award is granted under and governed by the terms and conditions of
the Company’s Award Plan as amended and the Award Agreement, all of which are
attached and made a part of this document.
 
	 	 	 
	 

	 	 
	Alexza Pharmaceuticals, Inc.

	 	Date
	 
	 	 
	 

	 	 
	Name:

	 	Date

Page 1 of 1

Date:                    

Time:                    

 

 

Alexza Pharmaceuticals, Inc.

2005 Equity Incentive Plan

Stock Unit Award Agreement

     Pursuant to the Stock Unit Grant Notice (“Grant Notice”) and this Stock Unit Award Agreement
(“Agreement”) (collectively, the “Award”), Alexza Pharmaceuticals, Inc. (the “Company”) has awarded
you, pursuant to its 2005 Equity Incentive Plan (the “Plan”), the number of Stock Units as
indicated in the Grant Notice. As used herein, “Stock Unit” means a notional unit representing the
right to receive one share of Company Common Stock. Defined terms not explicitly defined in this
Agreement but defined in the Plan shall have the same definitions as in the Plan.

     The details of your Award are as follows.

     1. Vesting. Subject to the Plan and the limitations contained herein, your Award
shall vest as provided in the Grant Notice, provided that vesting shall cease upon the termination
of your Continuous Service. Any Stock Units that have not vested shall be forfeited upon the
termination of your Continuous Service.

     2. Dividends. You shall not receive any payment or other adjustment in the number of
your Stock Units for dividends or other distributions that may be made in respect of the shares of
Common Stock to which your Stock Units relate.

     3. Evidence of Share Issuance. Subject to Section 10 below, your vested Stock Units
shall be converted into shares of Common Stock as of their vesting date and the certificates
representing such shares or other evidence of issuance will be delivered to you as soon as
practicable after each vesting date.

     4. Number of Shares. The number of Stock Units subject to your Award may be adjusted
from time to time for capitalization adjustments, as provided in Section 10(a) of the Plan.

     5. Securities Law Compliance. You may not be issued any shares of Common Stock under
your Award unless the shares are either (i) then registered under the Securities Act or (ii) the
Company has determined that such issuance would be exempt from the registration requirements of the
Securities Act. Your Award must also comply with other applicable laws and regulations governing
the Award, and you shall not receive such shares if the Company determines that such receipt would
not be in material compliance with such laws and regulations.

     6. Restrictive Legends. The shares of Common Stock issued under your Award shall be
endorsed with appropriate legends, if any, determined by the Company.

     7. Transferability. Your Award is not transferable, except by will or by the laws of
descent and distribution. Notwithstanding the foregoing, by delivering written notice to the
Company, in a form satisfactory to the Company, you may designate a third party who, in the

1.

 

event of your death, shall thereafter be entitled to receive any distribution of shares of
Common Stock pursuant to Section 3 of this Agreement.

     8. Award not a Service Contract. Your Award is not an employment or service
contract, and nothing in your Award shall be deemed to create in any way whatsoever any obligation
on your part to continue in the service of the Company or an Affiliate, or on the part of the
Company or an Affiliate to continue such service. In addition, nothing in your Award shall
obligate the Company or an Affiliate, their respective stockholders, boards of directors, Officers
or Employees to continue any relationship that you might have as an Employee, Director or
Consultant for the Company or an Affiliate.

     9. Unsecured Obligation. Your Award is unfunded, and as a holder of vested Stock
Units subject to your Award, you shall be considered an unsecured creditor of the Company with
respect to the Company’s obligation, if any, to issue shares of Common Stock pursuant to Section 3
of this Agreement.

     10. Withholding Obligations.

          (a) At the time vested Stock Units are converted into shares of Common Stock pursuant to your
Award, or at any time thereafter as requested by the Company, you hereby authorize any required
withholding from payroll and any other amounts payable to you and otherwise agree to make adequate
provision for any sums required to satisfy the federal, state, local and foreign tax withholding
obligations of the Company or an Affiliate, if any, which arise in connection with your Award.
[Such withholding obligations may be satisfied by your relinquishment of your right to receive a
portion of the shares otherwise issuable to you in respect of vested Stock Units pursuant to the
Award; provided, however, that you shall not be authorized to relinquish your right to shares with
a fair market value in excess of the amount required to satisfy the minimum amount of tax required
to be withheld by law.]

          (b) Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied,
the Company shall have no obligation to issue such shares.

     11. Notices. Any notices provided for in your Award or the Plan shall be given in
writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by
the Company to you, five (5) days after deposit in the United States mail, postage prepaid,
addressed to you at the last address you provided to the Company.

     12. Headings. The headings of the Sections in this Agreement are inserted for
convenience only and shall not be deemed to constitute a part of this Agreement or to affect the
meaning of this Agreement.

     13. Amendment. Nothing in this Agreement shall restrict the Company’s ability to
exercise its discretionary authority pursuant to Sections 3 and 11 of the Plan; provided, however,
that no such action may, without your consent, adversely affect your rights under your Award and
this Agreement.

2.

 

     14. Miscellaneous.

          (a) The rights and obligations of the Company under your Award shall be transferable to any
one or more persons or entities, and all covenants and agreements hereunder shall inure to the
benefit of, and be enforceable by the Company’s successors and assigns.

          (b) You agree upon request to execute any further documents or instruments necessary or
desirable in the sole determination of the Company to carry out the purposes or intent of your
Award.

          (c) You acknowledge and agree that you have reviewed your Award in its entirety, have had an
opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully
understand all provisions of your Award.

     15. Governing Plan Document. Your Award is subject to all the provisions of the
Plan, the provisions of which are hereby made a part of your Award, and is further subject to all
interpretations, amendments, rules and regulations which may from time to time be promulgated and
adopted pursuant to the Plan. In the event of any conflict between the provisions of your Award
and those of the Plan, the provisions of the Plan shall control.

     16. Choice of Law. The interpretation, performance and enforcement of this Agreement
shall be governed by the law of the state of California without regard to such state’s conflicts of
laws rules.

3.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]